← All trials
NCT06728176
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2024
- Primary completion
- Feb 28, 2025
- Completion date
- Feb 28, 2025
- First posted
- Dec 11, 2024
- Last posted
- Dec 11, 2024
- Enrollment
- 38
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Monument Therapeutics LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.